Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant peritoneal mesothelioma.

B W Loggie1

  • 1Department of Surgery, Division of Surgical Oncology, The University of Texas Southwestern Medical Center at Dallas, 1400 Eighth Avenue, Suite 101, Fort Worth, TX 76104, USA. bloggie@cans.org

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion.

Perfusion·2002
Same author

Prospective trial for the treatment of malignant peritoneal mesothelioma.

The American surgeon·2001
Same author

Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2001
Same author

CT appearance of disseminated peritoneal adenomucinosis.

Abdominal imaging·2001
Same author

Sentinel lymph node mapping for carcinoma of the colon: a pilot study.

The American surgeon·2001

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy (CS-IPHC) offers a promising treatment for peritoneal malignant mesothelioma, improving symptoms and ascites. This approach provides acceptable morbidity and mortality with a 27-month median survival.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Peritoneal malignant mesothelioma is rare, with limited systemic chemotherapy options and poor response rates.
  • Malignant ascites and bowel obstruction are common, significantly impacting patient morbidity and mortality.
  • Current imaging techniques often understage peritoneal disease, complicating treatment planning.

Purpose of the Study:

  • To evaluate the author's approach using cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CS-IPHC) for peritoneal malignant mesothelioma.
  • To assess the efficacy of CS-IPHC in managing symptoms, ascites, and obstruction.
  • To determine the safety and survival outcomes associated with this combined treatment modality.

Main Methods:

  • Surgical staging for accurate disease assessment.

Related Experiment Videos

  • Tumor debulking, and surgical management of bowel obstruction.
  • Intraoperative hyperthermic chemotherapy perfusion (IPHC) following cytoreductive surgery (CS).

    • Main Results:

    • Rapid clinical symptom improvement and durable resolution of malignant ascites.
    • Acceptable morbidity and mortality rates associated with the CS-IPHC procedure.
    • A median survival of approximately 27 months was observed in treated patients.

    Conclusions:

    • CS-IPHC is an effective approach for peritoneal malignant mesothelioma, addressing staging, debulking, and ascites.
    • The procedure offers significant symptom relief and improved survival compared to conventional chemotherapy.
    • Further research is needed to develop effective systemic therapies to consolidate treatment gains.